David Z. Drew, MD

Photo of David Z. Drew, MD
(954) 267-7799
Mandarin Chinese
Hematology and Oncology
Holy Cross Medical Group: 

Office Hours
Monday-Friday  9:00 am to 12:00 pm, 1:00 pm to 4:00 pm

Click here to view Dr. Drew's Webisode
Click here for a PDF of Dr. Drew's May 2016 Lung Cancer presentation
likc here to view Dr. Drew's Anterior Approach to Bone Marrow Biopsy for Clinicians  

Focus Areas
General adult oncology with special emphasis on benign/malignant hematology and lung cancer

American Board of Internal Medicine
American Board of Internal Medicine - Hematology and Medical Oncology

Residency / Fellowship
Oncology/Hematology Clinical Fellow, National Institute of Health/ National Cancer Institute/National Heart Lung and Blood Institute, Bethesda, MD, 2006-2009
Internal Medicine Internship and Residency, Cincinnati Jewish Hospital, Cincinnati, OH, 2001-2004

Higher Education
Nanjing Medical College of TCM, Nanjing, China, M.D., 1992

GYN 19 - A Randomized Phase Ii Study of Paclitaxel/Carboplatin with or Without Sorafenib in the First-Line Treatment of Patients with Stage Ill/Iv Epithelial Ovarian Cancer,   sub-PI, 2010,  Holy Cross Hospital

CA184-035 - A Multicenter Treatment Protocol for Expanded Access Use ofIpilimumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage III orStage IV Melanoma   sub-PI, 2010,  Holy Cross Hospital

LYM66 (PI) - Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma    PI, 2011,  Holy Cross Hospital

VALOR study (PI) – A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients with  First Relapsed or Refractory Acute Myeloid Leukemia,  PI,  Holy Cross Hospital



4725 N. Federal Highway Cancer Center
33308 Fort Lauderdale , FL

HCMG Practice Locations